Longitudinal 18F-FDG Images in Patients With Alzheimer Disease Over More Than 9 Years From a Preclinical Stage.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
13
2
2020
medline:
7
7
2020
entrez:
13
2
2020
Statut:
ppublish
Résumé
Brain F-FDG uptake reportedly starts to decline more than 10 years before the onset of cognitive decline in dominantly inherited Alzheimer disease (AD). We compared longitudinal F-FDG images in sporadic AD to aging data from a large sample size to expand the current knowledge of F-FDG reduction for AD progression. Participants comprised 2 individuals (subjects A and B at ages 65 and 68 years, respectively) and 107 control subjects (67.9 [SD, 4.9] years). Subject A underwent F-FDG PET a total of 8 times over 9 years from the preclinical to early dementia stages. Subject B underwent F-FDG PET a total of 11 times over 12 years from the preclinical to mild cognitive impairment stages. Control subjects underwent F-FDG PET twice over a mean follow-up period of 7.8 years. After placing the volume of interest on the AD-related hypometabolic regions, the longitudinal F-FDG images were compared among the subjects and control subjects. For the control group, the rate of F-FDG reduction was 2.2% per decade (ie, aging effects). The rates of F-FDG reduction were 9.41% over 9 years and 9.07% over 12 years in subjects A and B, respectively. We estimated that F-FDG uptake started to decrease 4 and 2 years before indications of memory loss in subjects A and B, respectively. The present study suggests that the time between the beginning of F-FDG reduction and the onset of cognitive decline may be shorter in elderly individuals with AD compared with the recently estimated period in dominantly inherited AD.
Sections du résumé
BACKGROUND
BACKGROUND
Brain F-FDG uptake reportedly starts to decline more than 10 years before the onset of cognitive decline in dominantly inherited Alzheimer disease (AD). We compared longitudinal F-FDG images in sporadic AD to aging data from a large sample size to expand the current knowledge of F-FDG reduction for AD progression.
METHODS
METHODS
Participants comprised 2 individuals (subjects A and B at ages 65 and 68 years, respectively) and 107 control subjects (67.9 [SD, 4.9] years). Subject A underwent F-FDG PET a total of 8 times over 9 years from the preclinical to early dementia stages. Subject B underwent F-FDG PET a total of 11 times over 12 years from the preclinical to mild cognitive impairment stages. Control subjects underwent F-FDG PET twice over a mean follow-up period of 7.8 years. After placing the volume of interest on the AD-related hypometabolic regions, the longitudinal F-FDG images were compared among the subjects and control subjects.
RESULTS
RESULTS
For the control group, the rate of F-FDG reduction was 2.2% per decade (ie, aging effects). The rates of F-FDG reduction were 9.41% over 9 years and 9.07% over 12 years in subjects A and B, respectively. We estimated that F-FDG uptake started to decrease 4 and 2 years before indications of memory loss in subjects A and B, respectively.
CONCLUSIONS
CONCLUSIONS
The present study suggests that the time between the beginning of F-FDG reduction and the onset of cognitive decline may be shorter in elderly individuals with AD compared with the recently estimated period in dominantly inherited AD.
Identifiants
pubmed: 32049727
doi: 10.1097/RLU.0000000000002948
pii: 00003072-202004000-00024
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e185-e189Références
Patwardhan MB, McCrory DC, Matchar DB, et al. Alzheimer disease: operating characteristics of PET—a meta-analysis. Radiology. 2004;231:73–80.
Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–2127.
Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer's disease—a systematic review. Eur J Radiol. 2017;94:16–24.
Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119–128.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–292.
Weiner MW, Veitch DP, Aisen PS, et al. 2014 Update of the Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2015;11:e1–e120.
Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018;17:241–250.
Wu L, Rowley J, Mohades S, et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One. 2012;7:e47905.
Sakurai R, Yasunaga M, Murayama Y, et al. Long-term effects of an intergenerational program on functional capacity in older adults: results from a seven-year follow-up of the REPRINTS study. Arch Gerontol Geriatr. 2016;64:13–20.
Ishibashi K, Onishi A, Fujiwara Y, et al. Longitudinal effects of aging on 18F-FDG distribution in cognitively normal elderly individuals. Sci Rep. 2018;8:11557.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–279.
Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804.
Ossenkoppele R, Tolboom N, Foster-Dingley JC, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2012;39:990–1000.
Shokouhi S, Claassen D, Kang H, et al. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med. 2013;54:1564–1569.